SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 22, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Impairment loss		$ 0	$ 0	$ 4,600,000	$ 0
Clawback expected gross profit				8,000,000.0
Cash		4,400,000		4,400,000
Goodwill impairment loss		2,000,000.0	0	4,700,000	0
Accumulated deficit		(112,800,000)		(112,800,000)
Allowance for doubtful accounts		0		0		$ 1,000
Research and development		30,000.00	600,000	500,000	1,900,000
Contract liabilities		$ 400,000		$ 400,000		$ 300,000
Maximum share receivale upon achievement of certain sales milestones		5,988,024		5,988,024
Common Stock conversion price				$ 1.32
Advertising costs		$ 700,000	700,000	$ 1,400,000	2,200,000
Gain (loss) from change in fair value of Series A and B convertible notes		$ 400,000	800,000	$ 700,000	1,100,000
Valuation allowance percentage		100.00%		100.00%
Asset purchase agreement Description	total consideration paid at closing in the amount of $20.0 million, which consisted of (i) the cancellation of indebtedness owed by CURE to the Buyer in the amount of $4.15 million, (ii) a $2.0 million one-year note payable in the form of a secured promissory note, and (iii) the remainder in cash.
Working capital deficit		$ 6,600,000		$ 6,600,000
FDIC insured amount		250,000		250,000
Excess in FDIC insured amount		4,000,000.0		4,000,000.0
Gross profit		1,428,000	$ 914,000	3,140,000	$ 3,210,000
Gross profit
Gross profit				6,000,000.0
Cash [Member]
Cash		$ 50,000		$ 50,000